Abstract
Background: To evaluate the potential added benefit of opicapone (OPC), versus placebo (PLC) and entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson's disease (PD) patients from the BIPARK-I trial who were recently diagnosed with motor fluctuations ('recent fluctuators'; defined as having an onset of motor fluctuations < /=1 year of study baseline).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
